Harmony Biosciences Holdings Inc
(NAS:HRMY)
$
30.135
1.32 (4.58%)
Market Cap: 1.71 Bil
Enterprise Value: 1.53 Bil
PE Ratio: 13.05
PB Ratio: 3.32
GF Score: 62/100 - Q1 2024 Harmony Biosciences Holdings Inc Earnings Call TranscriptApr 30, 2024$30.91 (+5.68%)Earnings
- Q4 2023 Harmony Biosciences Holdings Inc Earnings Call TranscriptFeb 22, 2024$31.45 (-4.70%)Earnings
- Harmony Biosciences Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Harmony Biosciences Holdings Inc Earnings Call TranscriptOct 31, 2023$23.54 (+19.43%)Earnings
- Harmony Biosciences Holdings Inc To Acquire Zynerba Pharmaceuticals Inc- M&A Call TranscriptAug 14, 2023
- Q2 2023 Harmony Biosciences Holdings Inc Earnings Call TranscriptAug 01, 2023$33.99 (-3.90%)Earnings
- Harmony Biosciences Holdings Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 Harmony Biosciences Holdings Inc Earnings Call TranscriptMay 02, 2023$33.55 (+2.41%)Earnings
- Q4 2022 Harmony Biosciences Holdings Inc Earnings Call TranscriptFeb 21, 2023$43.81 (-11.08%)Earnings
- Harmony Biosciences Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Q3 2022 Harmony Biosciences Holdings Inc Earnings Call TranscriptNov 01, 2022$59.26 (+13.96%)Earnings
- Q2 2022 Harmony Biosciences Holdings Inc Earnings Call TranscriptAug 02, 2022$55.42 (+12.57%)Earnings
- Q1 2022 Harmony Biosciences Holdings Inc Earnings Call TranscriptMay 03, 2022$37.18 (-17.56%)Earnings
- Harmony Biosciences Holdings Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Harmony Biosciences Holdings Inc at Needham Neuroscience Forum (Virtual) TranscriptMar 16, 2022
- Q4 2021 Harmony Biosciences Holdings Inc Earnings Call TranscriptFeb 28, 2022$39.96 (+5.35%)Earnings
- Harmony Biosciences Holdings Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Q3 2021 Harmony Biosciences Holdings Inc Earnings Call TranscriptNov 09, 2021$42.18 (-0.94%)Earnings
- Q2 2021 Harmony Biosciences Holdings Inc Earnings Call TranscriptAug 10, 2021$30.16 (+12.66%)Earnings
- Harmony Biosciences Holdings Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Harmony Biosciences Holdings Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Harmony Biosciences Holdings Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 02, 2021
- Q1 2021 Harmony Biosciences Holdings Inc Earnings Call TranscriptMay 11, 2021$25.96 (-3.13%)Earnings
- Q4 2020 Harmony Biosciences Holdings Inc Earnings Call TranscriptMar 25, 2021$29.75 (+3.48%)Earnings
- Harmony Biosciences Holdings Inc at Piper Sandler Healthcare Conference (Virtual)- Pre-recorded Firside Chat TranscriptNov 30, 2020
- Q3 2020 Harmony Biosciences Holdings Inc Earnings Call TranscriptNov 12, 2020$43.94 (-7.44%)Earnings
Harmony Biosciences Holdings Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021 / 07:50PM GMT
Release Date Price:
$32.64
(-0.43%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Well, good afternoon, everyone. Welcome to the 3:50 p.m. session on day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover U.S. and European biopharma names for the firm, and it's my great pleasure to be hosting Harmony Biosciences in a fireside chat discussion today.
And joining us from the company, CEO, John Jacobs; and CFO, Sandip Kapadia. Welcome, gentlemen. It's good to see you.
John Charles Jacobs
Harmony Biosciences Holdings, Inc. - President, CEO & Director
Thank you, Graig. Same here.
Questions & Answers
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Great. I think a great place to start is just kind of maybe, John, you telling us a little bit more about the Harmony story. A relatively new company and a new publicly traded
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)